Stryker Corporation (SYK)
Technical, fundamental, and sentiment analysis with recent related videos.
SYK rates Neutral overall. The fundamental read is bullish: the company passes 5 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 4.01); revenue is growing about 10.8% per year; net income is growing about 12.4% per year. The technical picture is neutral: price is 5.3% below the 200-day moving average; 3.9% above the 50-day; the 50/200 relationship is in a Death cross. Sentiment is bullish (composite 75/100), based on 4 news articles from recent coverage.
Revenue 3-year avg +10.8%. Net income 3-year avg +12.4%.
Price vs 20DMA +6.5%. RSI 63.36. Bollinger state: Inside Bands.
Composite score 75/100 from the AI judge, based on 4 news items, 0 television segments, and 0 videos.
Latest Market Read
Stryker’s badges split the story. Fundamentals are Bullish: revenue averaged 10.8 percent per year and net income averaged 12.4 percent per year over three years. Technical sits Neutral, price is about 6.5 percent above its 20-day moving average (20-day moving average), the Relative Strength Index (RSI), a momentum reading, is 63.4, and the stock trades inside the Bollinger Bands. Sentiment is Bullish with a 75 composite score. The combination yields an Overall Neutral rating because technical caution (low volume and position below the 200-day average) offsets the strong fundamentals and positive sentiment.
Recent news: Global Database of Events, Language, and Tone (GDELT) and Internet Archive TV coverage focus on Stryker’s completed acquisition of ZuriMED on Oct. 26, 2026, adding the FiberLocker System and shoulder-care assets, plus FDA 510(k) clearance for Sonopet 3. Sources are generally positive about those product and portfolio moves, while also flagging near-term scrutiny around Q3 results, organic sales, procedure volumes, margins and guidance. Recent videos also flagged reports of cyberattacks affecting medical-device makers, including Stryker.